Federated Hermes
RLMD icon

Federated Hermes’s Relmada Therapeutics RLMD Stock Holding History

Federated Hermes’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-87,425
Closed -$283K – 2171
2024
Q3 		$283K Sell
87,425
-8,585
-9% -$27.8K ﹤0.01% 1432
2024
Q2 		$288K Hold
96,010
– – ﹤0.01% 1421
2024
Q1 		$446K Sell
96,010
-3,829
-4% -$18.5K ﹤0.01% 1351
2023
Q4 		$413K Sell
99,839
-14,363
-13% -$42.5K ﹤0.01% 1388
2023
Q3 		$343K Buy
114,202
+78
+0.1% +$232 ﹤0.01% 1436
2023
Q2 		$281K Buy
+114,124
New +$315K ﹤0.01% 1508

Other funds holding RLMD

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Federated Hermes's RLMD Position: Q4 2024 in Review

Federated Hermes sold out of Relmada Therapeutics (RLMD) in Q4 2024, closing a stake of 87,425 shares — an estimated $283K sold.

Federated Hermes first reported a position in RLMD in Q2 2023 and held it in 6 quarters. The position peaked at $446K in Q1 2024. 48 funds tracked by Wall St. Rank hold RLMD as of Q4 2024.

  • Federated Hermes reported no remaining Relmada Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Federated Hermes sold 87,425 Relmada Therapeutics shares in Q4 2024, an estimated $283K.
  • Federated Hermes first reported a position in Relmada Therapeutics in Q2 2023 and held it in 6 quarters.
  • Federated Hermes's Relmada Therapeutics position peaked at $446K in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2024.

Based on Federated Hermes's 13F filing for Q4 2024, filed 13 Feb 2025.